Bicara Therapeutics (BCAX) Treasury Shares (2023 - 2024)
Bicara Therapeutics (BCAX) posted quarterly Treasury Shares of $119.6 million for Q2 2024, little changed quarter-over-quarter from $119.6 million in Q1 2024.
Bicara Therapeutics (BCAX) Treasury Shares (2023 - 2024) Analysis & Trends
Bicara Therapeutics' Treasury Shares history runs 2 years deep, the most recent figure standing at $119.6 million for Q2 2024.
- In Q2 2024, Treasury Shares changed N/A year-over-year to $119.6 million; the TTM figure through Jun 2024 stood at $119.6 million (changed N/A YoY), while the FY2023 annual figure was $119.6 million, changed N/A from the prior year.
- Treasury Shares for Q2 2024 stood at $119.6 million, roughly flat from $119.6 million in the prior quarter.
- The five-year high for Treasury Shares was $119.6 million in Q4 2023, with the low at $81.8 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 7.00 Mn |
| Sep 30, 2024 | 7.00 Mn |
| Jun 30, 2024 | 119.60 Mn |
| Jun 30, 2024 | 119.60 Mn |
| Mar 31, 2024 | 119.60 Mn |
| Mar 31, 2024 | 119.60 Mn |
| Dec 31, 2023 | 119.60 Mn |
| Dec 31, 2023 | 119.60 Mn |
| Sep 30, 2023 | 81.79 Mn |
| Sep 30, 2023 | 81.79 Mn |